Dr. Winter on Checkpoint Inhibitors for Hodgkin Lymphoma

Video

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Checkpoint inhibition might have some toxicity issues, explains Winter. However, the CheckMate-205 trial, presented by Michelle A. Fanale, MD, at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, indicated that there has been little to no serious toxicity in the patients who received nivolumab (Opdivo).

Winter is hopeful that these agents for patients with Hodgkin lymphoma will have a low toxicity profile.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD